Beclometasone oral - Soligenix

Drug Profile

Beclometasone oral - Soligenix

Alternative Names: BDP; DOR 201; DOR 202; DOR 203; Oral BDP - Soligenix/Sigma-Tau; Oral beclomethasone 17,21-dipropionate; orBec; OrbeShield; SGX 201; SGX 202; SGX 203

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enteron Pharmaceuticals
  • Developer Fred Hutchinson Cancer Research Center; National Institutes of Health (USA); Soligenix
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Crohn's disease; Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • Phase I Crohn's disease
  • Preclinical Acute radiation syndrome
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 08 Dec 2016 Soligenix receives grant from National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA) for beclometasone oral development
  • 25 Jul 2016 Soligenix received additional grant from NIAID and BARDA for beclometasone oral preclinical development in gastrointestinal Acute radiation syndrome
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top